Sequani
Lee Coney is an accomplished Senior Business Leader with extensive experience in scientific, strategic, commercial development, regulatory affairs, and management within the pharmaceutical and CRO sectors. Currently serving as Chief Scientific Officer at Sequani since May 2023, Lee has held prominent roles including Head of Development and Head of Non-Clinical Safety at Cell and Gene Therapy Catapult from February 2020 to May 2023. Previous positions include Chief Scientific Officer at Envigo, Director of Biopharmaceutical Development at Huntingdon Life Sciences, and Product Development Manager at CellFactors, among others. Lee holds a BSc in Microbiology from the University of East London and possesses a strong passion for enhancing operations and fostering talent to achieve sustainable productivity gains.
This person is not in any teams
This person is not in any offices
Sequani
great people, great work, real results Sequani’s heritage spans more than 40 years when a company called Toxicol Laboratories opened for business in London. A little while later the company moved to the current site in Ledbury’s Bromyard Road. Toxicol Laboratories then joined with Quintiles and the foundations were laid for the company as it is today. The name Sequani dates back to the year 2000 when, after seven years of association with Quintiles, the company changed ownership under a new identity. The name Sequani comes from a Celtic tribe made famous for harrying invading Romans during their suppression of Gaul. We feel the name is apt as we too give the big boys a run for their money! We achieve this by working closely with you to deliver flexible and fast solutions that help keep your development programmes on schedule. Our customer feedback consistently shows that the service and commitment our clients enjoy is the most personal and direct in the business. But we take none of this for granted. Our focus is continuous improvement so that we carry on growing through the repeat business of loyal customers as well as attracting business from new clients.